Diversified medical device/supplies company focused on IV solutions/infusion systems, surgical/acute care products and injectable pharmaceuticals.
Diversified medical device/supplies company focused on IV solutions/infusion systems, surgical/acute care products and injectable pharmaceuticals.
Hospitals buy IV solutions, pumps and consumables under multi-year supply contracts, so the installed pumps pull through recurring sales of tubing and fluids. In 2025 it sold most of its kidney-care business to Carlyle as Vantive, keeping a minority stake, after selling its biopharma contract-manufacturing unit in 2023.
Moat: narrow (installed base, switching costs, scale). Broad installed base of IV/infusion equipment and long-standing hospital supply relationships.
Headquarters: Deerfield, Illinois, USA · Founded: 1931 · Employees: 37,500
Size Baxter International (BAX) is a United States Health Care company (Medical Specialties) with a market value of $13.5B, the 641st largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.16 on 18 Nov 2026.
Performance Over six months the shares gained 39.4%, against +25.3% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 5.3% over the last twelve months (peer median +5.9%); the operating margin is 5.9% (peer median 16.4%).
Valuation It trades at 12.7× forward earnings against a peer median of 20.0× (2nd cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.0 points below its cost of capital (7.4% WACC).
Backlog Backlog (remaining performance obligations) was $7.58B at 30 Sep 2026, down 23% on a year earlier — 0.7 years of trailing revenue. Backlog detail →
Credit Baxter International has 12 bonds outstanding ($8.28B), rated BBB- by the agencies and trading like BBB- at a weighted spread of 115 bp.
Short interest Short interest is 4.6% of the free float (30 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $11.6B | $11.2B | $10.6B | $10.4B | $14.5B |
| Revenue growth | — | +6% | +3% | -29% | — |
| Gross profit | $3.71B | $3.71B | $3.85B | $3.99B | $5.53B |
| EBITDA | $1.64B | $1.67B | $1.68B | $1.89B | $3.02B |
| Net income | -$705M | -$1.05B | -$649M | -$226M | -$2.43B |
| Free cash flow | $1.14B | $332M | $573M | $1.29B | $591M |
| Capital expenditure | $506M | $522M | $446M | $432M | $620M |
| Total debt | $8.01B | $9.78B | $13.4B | $14.1B | $17.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Baxter International BAX | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% |
| Fresenius Medical Care AG Sponsored ADR FMS | $11.6B | -6% | +4% | 11% | 9.2× | -3.3% |
| Becton Dickinson BDX | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% |
| ICU Medical ICUI | $4.46B | +38% | -6% | 8% | 19.4× | 18.9% |
| Fresenius SE & Co. KGaA FRE.DE | $32.7B | +41% | +7% | 10% | 14.7× | 7.0% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| Hikma Pharmaceuticals HIK.L | $4.58B | +15% | +2% | 20% | 9.8× | 2.0% |
| Teleflex TFX | $6.58B | +23% | -29% | 12% | 16.7× | 16.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BAX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.7% | +4.2% | 6th highest of 21 |
| 6-month return | +39.4% | +25.3% | 8th highest of 21 |
| Distance from 52-week high | -12.8% | -15.2% | 10th highest of 21 |
| Revenue growth (TTM) | +5.3% | +5.9% | 11th highest of 21 |
| Operating margin | 5.9% | 16.4% | 3rd lowest of 21 |
| Forward P/E | 12.7× | 20.0× | 2nd cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 13.4% | 10.6% | 7th most demanding of 18 |
| Growth delivered (Del g) | -0.7% | +8.3% | 2nd lowest of 18 |
| Hurdle (Req g minus delivered) | +14.1 pp | +4.2 pp | 5th most demanding of 18 |
| ROIC minus cost of capital | -3.0 pp | +0.9 pp | 7th lowest of 21 |
| EV / EBITDA | 11.9× | 14.0× | 9th cheapest of 18 |
| Net debt / EBITDA | 3.7× | 1.1× | most indebted of 18 |
| Bond spread | 115 bp | 106 bp | 2nd widest of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Baxter International BAX | United States | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% | -0.7% |
| Lenskart Solutions LENSKART.NS | India | $13.6B | +49% | +35% | 10% | 137.7× | 53.2% | +33.5% |
| Glaukos GKOS | United States | $13.8B | +62% | +47% | -9% | 161.5× | n/a | n/a |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.4B | +4% | +27% | 9% | 45.7× | n/a | n/a |
| Olympus 7733.T | Japan | $12.7B | +5% | +9% | 18% | 18.7× | -6.5% | +6.7% |
| Penumbra PEN | United States | $12.6B | -2% | +17% | 12% | 55.7× | 30.7% | +20.2% |
| Smith & Nephew SN..L | United Kingdom | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% | +5.6% |
| bioMerieux BIM.PA | France | $11.8B | +26% | -3% | 15% | 20.2× | 8.6% | +5.5% |
| Align Technology ALGN | United States | $11.6B | 0% | +4% | 19% | 13.8× | 13.1% | +10.3% |
| Cooper Companies (The) COO | United States | $11.6B | -2% | +5% | 19% | 13.4× | 9.4% | +11.0% |
| Coloplast A/S COLO-B.CO | Denmark | $16.6B | +24% | +4% | 25% | 20.0× | -2.1% | +8.3% |
| Revvity RVTY | United States | $17.0B | +61% | +5% | 16% | 26.2× | 26.4% | -5.5% |
| Avantor AVTR | United States | $10.4B | +95% | +1% | 8% | 17.5× | 16.4% | +0.5% |
| Demant A/S DEMANT.CO | Denmark | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% | +9.8% |
| Qiagen QGEN | United States | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% | +2.2% |
| Bio-Rad Laboratories BIO | United States | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% | +0.3% |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Zimmer Biomet ZBH | United States | $19.6B | +21% | +7% | 16% | 11.7× | 7.4% | +3.2% |
| Globus Medical GMED | United States | $9.34B | -16% | +13% | 23% | 13.7× | 4.6% | +30.1% |
| Guardant Health GH | United States | $19.6B | +26% | +42% | -39% | n/a | n/a | n/a |
Baxter International has 12 bonds outstanding with $8.28B face value. The agencies rate it BBB-; its bonds trade like BBB-. Weighted yield 5.71%, a spread of 115 bp over government bonds.
Baxter International reported $7.58B of remaining performance obligations at 30 Sep 2026, down 23% from a year earlier and down 4% from the previous quarter. That is 0.7 years of trailing revenue already under contract. Book-to-bill last quarter: 0.89.